Moderna和默沙东（MSD）今日公布了2b期KEYNOTE-942/mRNA-4157-P201研究的中位五年随访数据。该研究评估了在高风险黑色素瘤（III/IV期）患者完成根治性切除后，在研mRNA个体化癌症疫苗intismeran autogene（mRNA-4157或V940）联合PD-1抑制剂Keytruda（pembrolizumab）的疗效与安全性。分析显示，在中位随访5年时，与K ...

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

Cold chain logistics within pharmaceutical supply chains are undergoing a fundamental transformation as organizations confront rising product complexity, expanding global networks and mounting ...

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or causing death by nearly half compared with Keytruda alone.

Moderna announced that its seasonal flu vaccine mRNA-1010 demonstrated 26.6% relative vaccine efficacy compared with standard approved flu vaccines in a phase 3 efficacy trial in adults aged 50 and up ...

Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy (rVE) than an approved flu shot marketed by GSK plc GSK in a phase III ...

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the ...

The technical backdrop, however, points to caution. Seeking Alpha's momentum page flags Moderna as overbought on its relative strength index, with RSI levels indicating the stock has sprinted ahead of ...